Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Novel Combinations in Relapsed Hodgkin Lymphoma

January 26th 2018

Hodgkin Lymphoma: Addressing the Elderly Population

January 26th 2018

Hodgkin Lymphoma: Important Findings from CheckMate 205

January 26th 2018

Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline

January 26th 2018

ECHELON-1 Trial: Significance in Hodgkin Lymphoma

January 26th 2018

Novel Antibody Tested in First-Line DLBCL Therapy

January 25th 2018

Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.

Rituximab Biosimilar Succeeds in Phase III Follicular Lymphoma Trial

January 25th 2018

PF-05280586, a biosimilar for rituximab (Rituxan/MabThera), delivered positive top-line results in the phase III REFLECTIONS B3281006 follicular lymphoma trial.

CHOP-RIT Superior for PFS Versus R-CHOP in High-Risk Follicular Lymphoma

January 23rd 2018

The CHOP-RIT regimen improved progression-free survival compared with R-CHOP alone in previously untreated patients with follicular lymphoma.

Emerging Therapies for Follicular Lymphoma

January 23rd 2018

FL: Updated Data for Immunomodulatory Approaches

January 23rd 2018

Immunomodulatory Therapy for FL: The R-Squared Regimen

January 23rd 2018

Further Considerations for Relapsed/Refractory FL

January 23rd 2018

Treatment Approaches to Relapsed Refractory FL

January 23rd 2018

Optimizing Frontline Therapy and Maintenance in FL

January 23rd 2018

Frontline Treatment Approaches to Follicular Lymphoma

January 23rd 2018

FL: Monitoring to Initiate Therapy and Gauge Response

January 23rd 2018

Risk Stratification and Outcomes in Follicular Lymphoma

January 23rd 2018

Diagnosis and Staging for Follicular Lymphoma

January 23rd 2018

Brentuximab Vedotin Approved in Europe for CTCL

January 22nd 2018

Brentuximab vedotin (Adcetris) has been approved by the European Commission for the treatment of patients with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

Celgene Acquiring Juno Therapeutics for $9 Billion

January 22nd 2018

Celgene has announced plans to acquire Juno Therapeutics, maker of the CAR T-cell therapy lisocabtagene maraleucel (JCAR017), for $87 per share, totaling approximately $9 billion.